Cholera vaccine inactivated oral - Valneva
Alternative Names: Vibrio cholerae and enterotoxigenic Escherichia coli vaccine - Crucell/sanofi-aventis; Dukoral; SBL Cholera Vaccine; WC/rBS; whole cell/recombinant B subunit cholera vaccineLatest Information Update: 07 Jul 2025
At a glance
- Originator SBL Vaccin AB
- Developer Crucell; Valneva
- Class Cholera vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Cholera; Escherichia coli infections
Most Recent Events
- 26 Jun 2025 Valneva enters into marketing and distribution agreement with CSL Seqirus for cholera vaccine inactivated oral in Germany
- 03 Feb 2022 Sanofi Pasteur has been rebranded under Sanofi
- 18 Jun 2020 Bavarian Nordic and Valneva SE enters into an agreement for the marketing and distribution of Cholera vaccine inactivated oral in Germany and Switzerland